Amgen Stock Holds Steady After Strong Q2 Beat

Amgen's stock price has remained steady after the company reported a second-quarter beat and increased its 2026 earnings per share (EPS) guidance. The biotechnology giant finished the session at $432.42, with a market value of $233.78 billion, as investors digested the latest earnings update.

The quarter ended June 30, 2026, saw Amgen report revenue of $10.05 billion and adjusted EPS of $6.29 per share, surpassing the consensus estimate by $0.67. Revenue rose 9.5 percent from $9.19 billion a year earlier, while net margin stood at 22.95 percent and return on equity at 124.14 percent.

Management lifted 2026 EPS guidance to $22.30-$23.50 after the second-quarter results, with analysts clustering around $22.97 for the year. This leaves room for the market to focus on whether margins and product mix can hold up through the rest of 2026.